[go: up one dir, main page]

DE122006000007I1 - Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden. - Google Patents

Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.

Info

Publication number
DE122006000007I1
DE122006000007I1 DE19883853636 DE3853636C DE122006000007I1 DE 122006000007 I1 DE122006000007 I1 DE 122006000007I1 DE 19883853636 DE19883853636 DE 19883853636 DE 3853636 C DE3853636 C DE 3853636C DE 122006000007 I1 DE122006000007 I1 DE 122006000007I1
Authority
DE
Germany
Prior art keywords
ige
lymphocytes
bearing
exclusively
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19883853636
Other languages
English (en)
Other versions
DE3853636D1 (de
DE3853636T2 (de
DE3853636T3 (de
Inventor
Tse-Wen Chang
Bill Nai-Chau Sun
Cecily Rou-Yun Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27538114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122006000007(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/226,421 external-priority patent/US5422258A/en
Priority claimed from US07/272,243 external-priority patent/US5091313A/en
Application filed by Tanox Biosystems Inc filed Critical Tanox Biosystems Inc
Publication of DE122006000007I1 publication Critical patent/DE122006000007I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE19883853636 1987-12-31 1988-12-29 Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden. Pending DE122006000007I1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14003687A 1987-12-31 1987-12-31
US07/226,421 US5422258A (en) 1987-12-31 1988-07-29 Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US22917888A 1988-08-05 1988-08-05
US07/272,243 US5091313A (en) 1988-08-05 1988-11-16 Antigenic epitopes of IgE present on B cell but not basophil surface
US29106888A 1988-12-28 1988-12-28
PCT/US1988/004706 WO1989006138A1 (en) 1987-12-31 1988-12-29 UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES

Publications (1)

Publication Number Publication Date
DE122006000007I1 true DE122006000007I1 (de) 2006-04-27

Family

ID=27538114

Family Applications (3)

Application Number Title Priority Date Filing Date
DE19883853636 Pending DE122006000007I1 (de) 1987-12-31 1988-12-29 Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
DE3853636T Expired - Lifetime DE3853636T3 (de) 1987-12-31 1988-12-29 Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
DE122006000007C Active DE122006000007I2 (de) 1987-12-31 1988-12-29 -tragenden b-lymphocyten befinden.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE3853636T Expired - Lifetime DE3853636T3 (de) 1987-12-31 1988-12-29 Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
DE122006000007C Active DE122006000007I2 (de) 1987-12-31 1988-12-29 -tragenden b-lymphocyten befinden.

Country Status (10)

Country Link
EP (2) EP0617127A1 (de)
JP (1) JP2724625B2 (de)
AT (1) ATE121299T1 (de)
AU (1) AU618317B2 (de)
CA (1) CA1340233C (de)
DE (3) DE122006000007I1 (de)
HK (1) HK31096A (de)
LU (1) LU91218I2 (de)
NL (1) NL300222I2 (de)
WO (1) WO1989006138A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5089603A (en) * 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5362643A (en) * 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
EP0327283B1 (de) * 1988-02-02 1993-08-18 Schering Biotech Corporation Methode zur Verminderung der Immunglobulin-E-Reaktion
WO1991004055A1 (en) * 1989-09-15 1991-04-04 Tanox Biosystems, Inc. Treatment of autoimmune disease
ES2107454T3 (es) * 1990-01-23 1997-12-01 Tanox Biosystems Inc Segmentos extracelulares de peptidos de anclaje de la inmunoglobulina ige humana, y anticuerpos especificos para los mismos.
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
EP0602126B1 (de) * 1991-08-14 2003-03-05 Genentech, Inc. Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
US5994514A (en) * 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体
EP1452542A3 (de) * 1992-09-24 2007-05-02 Novartis AG Umgestaltete humane monoklonale Antikörper gegen IgE
GB9220228D0 (en) * 1992-09-24 1992-11-04 Ciba Geigy Ag Reshaped monoclonal antibodies against an immunologlobulin isotype
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
AU4661293A (en) * 1993-03-11 1994-09-26 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of ige present on b cell but not basophil surface
EP0619323A1 (de) * 1993-04-09 1994-10-12 Schering-Plough Menschliche monoklonale Antikörper und Verfahren und Material zu deren Herstellung
DK0739214T3 (da) * 1994-01-18 1998-10-07 Genentech Inc Fremgangsmåde til behandling af parasitinfektionerunder anvendelse af IgE antagonister
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP2788979B2 (ja) * 1995-08-28 1998-08-20 タノックス バイオシステムズ インコーポレイテッド 新規抗体及びその用途
JP2002508933A (ja) * 1997-12-24 2002-03-26 ダイアテック・ピーティワイ・リミテッド 二官能分子
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US6511814B1 (en) 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6602719B1 (en) 1999-03-26 2003-08-05 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP2301967A3 (de) 2002-11-08 2011-07-13 Ablynx N.V. Einzeldomänenantikörper zur nasalen Verabreichung
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
DK2000481T3 (en) 2003-02-01 2016-06-06 Tanox Inc High affinity anti-human IgE antibodies
AU2006297304B2 (en) 2005-09-29 2012-05-17 Medimmune, Llc Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
ES2478242T3 (es) 2007-03-22 2014-07-21 Genentech, Inc. Anticuerpos anti IgE apoptóticos que se unen con el IgE unido a membrana
EP1972640A1 (de) * 2007-03-23 2008-09-24 Biomay AG Apoptoseerzeugende Antikörper
RU2550270C2 (ru) 2009-02-25 2015-05-10 Академиа Синика АНТИ-CemX АНТИТЕЛА, СПОСОБНЫЕ СВЯЗЫВАТЬСЯ С migE ЧЕЛОВЕКА НА В ЛИМФОЦИТАХ
EP2838919A4 (de) 2012-04-20 2016-03-23 Academia Sinica An den übergang zwischen ch4- und c-epsilon-mx-domänen bindende anti-mige-antikörper
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof
CN111741768B (zh) 2017-10-31 2024-12-27 合一生技股份有限公司 治疗IgE介导的过敏性疾病

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946788A (en) * 1985-06-11 1990-08-07 Ciba-Geigy Corporation Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
US4714759A (en) * 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
ES2053561T3 (es) * 1986-11-04 1994-08-01 Baylor College Medicine Metodos y composiciones para inhibir cataratas secundarias.
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
GB8800078D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel antibodies

Also Published As

Publication number Publication date
AU3031089A (en) 1989-08-01
NL300222I1 (nl) 2006-04-03
CA1340233C (en) 1998-12-15
AU618317B2 (en) 1991-12-19
NL300222I2 (nl) 2006-10-02
HK31096A (en) 1996-03-01
DE3853636D1 (de) 1995-05-24
JP2724625B2 (ja) 1998-03-09
EP0407392B2 (de) 1998-10-28
JPH03501927A (ja) 1991-05-09
EP0407392B1 (de) 1995-04-19
ATE121299T1 (de) 1995-05-15
LU91218I2 (fr) 2006-04-03
WO1989006138A1 (en) 1989-07-13
EP0617127A1 (de) 1994-09-28
DE3853636T2 (de) 1995-08-24
DE122006000007I2 (de) 2008-03-27
DE3853636T3 (de) 1999-04-08
EP0407392A1 (de) 1991-01-16

Similar Documents

Publication Publication Date Title
DE122006000007I1 (de) Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
ATE47155T1 (de) Monoklonaler antikoerper.
DK69890D0 (da) Monoklonale antistoffer, der er reaktive med cachetin
ATE177475T1 (de) Monoklonale antikörper gegen c-kit
GR3030415T3 (en) Platelet activating factor antagonists.
FI874047A0 (fi) Monoklonaalisia vasta-ainemolekyylejä, joilla on katalyyttisiä ominaisuuksia omaavia vasta-aineen sitovia kohtia
IT1149290B (it) Polimeri idrocarburici ionici con migliorata adesione al nylon
ES2176347T3 (es) Modulacion de la respuesta inmune.
DE68922482D1 (de) Auflegevorrichtung für gummierte Bahnen.
FI842695A7 (fi) Erittäin tiheä mineraalikatkokuituperustainen yhdistelmäkalvo.
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
DE3882727D1 (de) Mycoplasma-membran-antigene und ihre verwendung.
DK191989D0 (da) Tumor-associeret glycoproteinantigen, antistoffer mod antigenet samt hybridoma-cellelinie, der producerer antistofferne
IT8121211A0 (it) Procedimento di conversione di olii pesanti di idrocarburi contenenti degli asfalteni, in frazioni piu'leggere.
BE881596A (fr) Dispositif passe-monnaie, notamment pour les banques, gares, grands magasins ou autres
IT8026986A0 (it) Antigene di prostata umana purificato e procedimento per preparare anticorpi correlati a tale antigene.
IT8021411A0 (it) Polipeptide sintetico attivo come antigene, e procedimento per la sua preparazione.
IT8522044A0 (it) Reforming degli idrocarburi superiori.
DE3785175D1 (de) A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung.
IT8420971A0 (it) Procedimento per la conversione di olifine in idrocarburi di peso molecolare piu' elevato con catalizzatore di silicalite.
ATE73463T1 (de) Monoklonale antikoerper.
NO803305L (no) Reflekstrakthoeyttaler med vanntettende anordning.
NO873154D0 (no) Spesifikke monoklonale antistoffer mot overflatereseptor for ige og hybridcellelinjer som produserer disse antistoffer og anvendelse derav.
SU887878A1 (ru) Демпфирующее устройство
IT8121653A0 (it) Caratteristiche di rigenerazione. catalizzatore per la conversione di idrocarburi dotato di migliori